Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, shares highlights from the BTOG 2022 Summer Meeting, including discussion surrounding the management of early lung cancer and the Phase III CHECKMATE-816 (NCT02998528) and NADIM (NCT03838159) trials showing promising data supporting the neoadjuvant treatment of lung cancer. This interview took place at the BTOG 2022 Summer Meeting congress in London.

свернуть